Literature DB >> 14649544

Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor.

Eugenia Scaccianoce1, Claudio Festuccia, Donatella Dondi, Vittoria Guerini, Mauro Bologna, Marcella Motta, Angelo Poletti.   

Abstract

Prostate cancer (PC) develops as a consequence of abnormal androgenic stimulation. Unfortunately, most of the PC cell lines are androgen independent (like DU145), or express mutated forms of androgen receptor (AR). We have produced and characterized a new stably transfected PC line expressing the AR (DU145-AR). Untreated DU145-AR cells showed a lower proliferation rate than mock transfected cells, but responded to testosterone treatment. PSA mRNA, undetectable in mock DU145 cells, was present and upregulated by testosterone in DU145-AR. About 5% of DU 145-AR cells showed modification of morphology and enriched of f-actin after testosterone treatment. Moreover, in DU145-AR plasminogen activator (PA) activity and secreted urokinase type plasminogen activator (uPA) protein were lower than in AR negative cells; again testosterone induced PA activity and uPA protein only in DU145-AR. These results indicate that, in general, the effects of unactivated AR is to suppress function(s) in DU145 cells and the addition of testosterone restores the normal properties associated with the untransfected cells. Some of the effects described may thus be mediated by a ligand-independent activation of AR in DU145 cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14649544     DOI: 10.3727/000000003108748658

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  7 in total

1.  p66Shc regulates migration of castration-resistant prostate cancer cells.

Authors:  Matthew A Ingersoll; Yu-Wei Chou; Jamie S Lin; Ta-Chun Yuan; Dannah R Miller; Yan Xie; Yaping Tu; Rebecca E Oberley-Deegan; Surinder K Batra; Ming-Fong Lin
Journal:  Cell Signal       Date:  2018-02-17       Impact factor: 4.315

Review 2.  The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.

Authors:  Sheng-Qiang Yu; Kuo-Pao Lai; Shu-Jie Xia; Hong-Chiang Chang; Chawnshang Chang; Shuyuan Yeh
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

3.  Statin derivatives as therapeutic agents for castration-resistant prostate cancer.

Authors:  Matthew A Ingersoll; Dannah R Miller; October Martinez; C Brent Wakefield; Kuan-Chan Hsieh; M Vijaya Simha; Chai-Lin Kao; Hui-Ting Chen; Surinder K Batra; Ming-Fong Lin
Journal:  Cancer Lett       Date:  2016-09-26       Impact factor: 8.679

4.  KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Patrizia Sanita; Flora Vitale; Francesco Marampon; Luca Ventura; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Claudio Festuccia
Journal:  BMC Cancer       Date:  2015-12-01       Impact factor: 4.430

5.  The Role of Radiofrequency Hyperthermia in The Radiosensitization of A Human Prostate Cancer Cell Line.

Authors:  Azam Janati Esfahani; Seied Rabi Mahdavi; Mohammad Bagher Shiran; Samideh Khoei
Journal:  Cell J       Date:  2017-05-17       Impact factor: 2.479

Review 6.  Loss and revival of androgen receptor signaling in advanced prostate cancer.

Authors:  Nicolò Formaggio; Mark A Rubin; Jean-Philippe Theurillat
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

7.  Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.

Authors:  Qi Li; Yibo Shi; Rigai Sa; Jun Hao; Jinhao Hu; Mulun Xiao; Chaoliang Wang; Liang Yan; Baoping Qiao; Guoxun Chen
Journal:  BMC Cancer       Date:  2020-06-15       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.